Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 149238.64 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-12-2020, the company reported a Consolidated Total Income of Rs 9151.73 Crore, up 3.89 % from last quarter Total Income of Rs 8808.91 Crore and up 10.60 % from last year same quarter Total Income of Rs 8274.73 Crore. Company reported net profit after tax of Rs 1918.11 Crore in latest quarter.
Investment Rationale
Revenues are likely to grow 7% YoY to | 8760 crore led by 10% growth in domestic and 12% growth in both RoW and Emerging Markets. US is expected to grow ~2.2% YoY to Rs 2773 crore amid continued traction in speciality portfolio. Taro’s sales are expected to decline 22% YoY on constant currency basis amid high base effect and continued pressure on dermatology portfolio. EBITDA margins are expected to improve 635 bps YoY to 23% mainly due to marketing, travel expenses and a better product mix. Adjusted net profit is expected to grow 120.2% to Rs 1455 crore
Promoter/FII Holdings
Promoters held 54.5 per cent stake in the company as of Dec 30, 2020, while FIIs held 12.2 per cent, DIIs 20.8 per cent and public and others 12.5 per cent.
